Watson to Commercialize Antares OAB Gel in U.S., Canada

Watson Pharmaceuticals has entered into an exclusive licensing agreement to commercialize Antares Pharma’s topical oxybutynin gel product, as a treatment for overactive bladder (OAB), in the U.S. and Canada.
PBR